A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
Study Details
Study Description
Brief Summary
A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Patients will be randomized in a 2:1 ratio.
Patients in the experimental arm will receive automatically generated personalized educational videos (PEV) and questionnaires regarding side effects and quality of life (QOL) to either their cell phone or email. The videos will be personalized to each patient based on their demographics, specific medical instructions and treatment plan. Data collected regarding side effects and QOL in the experimental arm will be used in order to facilitate real time intervention through real time provider alert system.
A link to the first PEV will be sent before the first chemotherapy cycle, addressing the diagnosis and type of malignancy, chemotherapy protocol, common side effects and their management. Side effects questionnaire will be sent every week while QOL questionnaire will be sent every 6 weeks.
Patients will be followed from recruitment through three weeks after completion of the planned treatment protocol. If treatment is discontinued prior to completion of the protocol, follow-up will end three weeks after the last administered treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: personalized engagement platform Patients registered into personalized engagement platform (PEP) will receive personalized educational videos (PEV) according to disease, treatment protocol and side effects. |
Other: patient engagement platform
Allows patients to receive the action plan as educational videos on demand.
Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan.
|
| No Intervention: control group The control group will not be registered to the PEP nor receive any PEVs. |
Outcome Measures
Primary Outcome Measures
- Feasibility of PEP (percent of patients using videos/complete questionnaires) [3 years]
To assess the feasibility of implementing a PEP in the outpatient gastrointestinal malignancies service, at Sheba Medical Center, for patients undergoing active chemotherapy treatment. This outcome will be measured as percent of patients using the videos and percent of patients that complete the questionnaires.
Secondary Outcome Measures
- Secondary clinical outcomes 1 (mean number of referrals) [3 years]
To monitor mean number of referrals to emergency room and admissions to the inpatient department.
- Secondary clinical outcomes 2 (level of chemotoxicity) [3 years]
To measure level of chemotoxicity - Neuropathy, diarrhea, nausea and vomiting, stomatitis and fever; using total number and percent of patients with side effects in each arm and Common Terminology Criteria for side effects (CTCAE) grading scale.
- Secondary clinical outcomes 3 (Quality of Life) [3 years]
To measure patient assessment of Quality of Life (QoL) using a validated questionnaire (QLQ-C30).
- Secondary clinical outcomes 4 (treatment intensity and continuity) [3 years]
To evaluate treatment intensity and continuity measured as number of chemotherapy cycles and cumulative chemotherapy dose.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Individuals with a newly diagnosed gastrointestinal malignancy, treated at the outpatient clinic of the Institute of Oncology at the Sheba Medical Center
-
Individuals planned to receive one of the following cytotoxic chemotherapy protocols:
-
FOLFOX - a combination of 5-fluoruracil, leucovorin and oxaliplatin.
-
FOLFOIRI - a combination of 5-fluoruracil, leucovorin and irinotecan.
-
FOLFIRINOX - a combination of 5-fluoruracil, leucovorin, oxaliplatin and irinotecan.
-
De Gramont - 5-fluoruracil and leucovorin.
-
Ability to read and comprehend Hebrew language text.
-
Ability to see computer or cell phone screen (i.e., no visual impairment).
Exclusion Criteria:
-
Eastern Conference Oncology Group (ECOG) performance status greater than 2.
-
Cognitive deficits that would preclude understanding of consent form and/or questionnaires.
-
Inability to read and comprehend Hebrew language text.
-
Current participation in a therapeutic clinical trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sheba Medical Center | Ramat Gan | Israel | 52621 |
Sponsors and Collaborators
- Sheba Medical Center
Investigators
- Principal Investigator: Ofer Margali, MD PhD, Sheba Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SHEBA-19-6013-YL-CTIL